ELVN Stock Summary and Trading Ideas (Enliven Therapeutics | NASDAQ:ELVN)

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.

As of February 20, 2026, ELVN stock price declined to $26.02 with 548,572 million shares trading.

ELVN has a beta of 0.97, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.04 to the broad based SPY ETF.

ELVN has a market cap of $1.54 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

ELVN has outperformed the market in the last year with a return of +21.2%, while the SPY ETF gained +14.1%. In the last 3 month period, ELVN beat the market returning +22.3%, while SPY returned +6.0%. However, in the most recent 2 weeks ELVN has underperformed the stock market by returning -11.6%, while SPY returned -0.2%.

ELVN support price is $25.17 and resistance is $27.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.